Figure 1.

Planned cumulative doses of drugs used in the low- and standard-risk arms of T15 and T16. The only drugs with at least a 10% difference in planned cumulative dosages between T16 and T15 (within risk arms) were asparaginase (34% higher in the standard risk arm), dexamethasone (17.4% lower in the standard- risk arm), and doxorubicin (50% less in the low-risk arm). Thus, only asparaginase was planned for higher dosages on T16 than on T15. There were no differences between T15 and T16 in planned cumulative dosages of prednisone, vincristine, daunorubicin, cytarabine, cyclophosphamide, mercaptopurine; there was a planned decrease of only 6.0% in low-dose methotrexate dosages in the standard-risk arm on T16 versus T15. See Online Supplementary Table S2 for details on planned dosages.